Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | EED | O75530 | 2/20 | 0.40 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.40 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837729 | 0.87 | GRM1 (0.44) | GRM5GRM1PDE10APDK4EED | |
| SCHEMBL17837491 | 0.86 | GRM1 (0.41) | GRM5GRM1PDE10APDK4EED | |
| SCHEMBL27193438 | 0.85 | EED (0.38) | GRM5GRM1PDE10APDK4EED | |
| SCHEMBL29900848 | 0.85 | GRM5 (0.41) | GRM5GRM1PDE10AEEDRBBP4 | |
| SCHEMBL17837904 | 0.85 | GRM1 (0.42) | GRM5GRM1PDE10APDK4EED | |
| SCHEMBL12874666 | 0.84 | GRM1 (0.49) | GRM5GRM1PDE10APDK4EED | |
| SCHEMBL29900928 | 0.83 | EED (0.38) | GRM5GRM1EEDRBBP4SUZ12 | |
| SCHEMBL29900919 | 0.82 | PIK3CA (0.37) | GRM5GRM1PDE10AEEDRBBP4 | |
| SCHEMBL24330001 | 0.81 | GRM5 (0.55) | GRM5GRM1PDE10APDK4NAMPT | |
| SCHEMBL29900931 | 0.81 | CYP11B2 (0.40) | GRM5GRM1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187520-A1 | SUBSTITUTED 3-PIPERIDINYL-PYRAZOLO[3,4-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | GRM5 1645/4885GRM1 1082/4885PDE10A 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.